Compare · PROF vs SYK
PROF vs SYK
Side-by-side comparison of Profound Medical Corp. (PROF) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PROF and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 593.5x PROF ($211.3M).
- Over the past year, PROF is up 48.4% and SYK is down 10.8% - PROF leads by 59.2 points.
- SYK has been more active in the news (5 items in the past 4 weeks vs 4 for PROF).
- SYK has more recent analyst coverage (25 ratings vs 7 for PROF).
- Company
- Profound Medical Corp.
- Stryker Corporation
- Price
- $7.05+4.60%
- $327.50-0.63%
- Market cap
- $211.3M
- $125.43B
- 1M return
- +20.72%
- -0.03%
- 1Y return
- +48.42%
- -10.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 7
- 25
Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PROF
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
- Profound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
- Profound Medical Corp. filed SEC Form 8-K: Leadership Update
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew